Elimination of the antiviral drug 5-ethyl-2'-deoxyuridine by the isolated perfused rat liver.
J M Joly, W M Williams
Index: Drug Metab. Dispos. 19(6) , 1058-65, (1991)
Full Text: HTML
Abstract
The elimination of the antiviral drug 5-ethyl-2'-deoxyuridine (EdUrd) by the isolated perfused rat liver was investigated. EdUrd (3.9-39 mumol) was injected into the perfusion reservoir and serial samples were collected for HPLC determination of EdUrd and its metabolites 5-ethyluracil (EUra) and 5-(1-hydroxyethyl)uracil (HEUra). At each dosage level, semilogarithmic plots of concentration vs. time showed apparent first order disappearance of EdUrd. However, with increasing dose, there was a progressive increase in EdUrd half-life from 18.9 to 36.4 min and decrease in total clearance from 5.5 to 2.5 ml/min, indicating dose-dependent elimination. Dose dependence was confirmed by the lack of superposition of logarithm concentration/dose vs. time plots obtained with different doses. After EdUrd administration, the concentration of EUra reached a peak value in about 1 hr, and then gradually decreased. The concentration of HEUra, which was initially much lower than that of EUra, increased throughout the experiment and appeared to approach a plateau at 2-3 hr. Biliary excretion of each ethylpyrimidine was negligible. 6-Benzyl-2-thiouracil, a thymidine phosphorylase inhibitor, slowed the disappearance of EdUrd and decreased the peak concentrations of EUra and HEUra. Cimetidine, a cytochrome P-450 inhibitor, had little effect on the rate of EdUrd disappearance, but caused a large increase in the peak EUra concentration and decrease in HeUra concentration. 3-Methylcholanthrene, a cytochrome P-450 inducer, increased the formation of HEUra but had little effect on the rate of EdUrd disappearance. The results indicate that the hepatic elimination of EdUrd is dose-dependent and involves an initial cleavage to EUra, which is then oxidized to HEUra.
Related Compounds
Related Articles:
2007-06-01
[Antimicrob. Agents Chemother. 51 , 2028-34, (2007)]
2012-10-24
[J. Neurosci. 32(43) , 15066-75, (2012)]
1988-07-01
[Antiviral Res. 9(4) , 263-72, (1988)]
1995-07-01
[J. Pharm. Pharmacol. 47(7) , 595-600, (1995)]
1989-02-01
[Arzneimittelforschung 39(2) , 220-2, (1989)]